Hepatic Impairment
Conditions
Keywords
Liver disease, Anti-neutrophil cytoplasmic antibody-associated vasculitis, Complement C5a receptor (C5aR)
Brief summary
The primary objective of this study will be to evaluate the pharmacokinetic properties of avacopan and its metabolite CCX168-M1 after a single oral dose of 30 mg avacopan in participants with mild or moderate hepatic impairment compared to matched healthy controls.
Interventions
DRUGAvacopan
Administered orally.
Sponsors
Amgen
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* An Institutional Review Board approved informed consent form is signed and dated prior to any study-related activities; * Adult male or female participants, aged ≥18 to ≤75 years of age inclusive; * Body mass index (BMI) ≥18.0 to ≤38.0 kg/m\^2, inclusive, at screening; * Female participants of childbearing potential or male participants with partners of childbearing potential may participate if adequate contraception is used during, and for at least 90 days after, any administration of study medication. Inclusion Criteria Specific for Participants with Hepatic Impairment: * Hepatic disease based on a documented history of hepatic insufficiency with features of cirrhosis and ability to classify hepatic disease as mild or moderate using C-P criteria; * No acute episodes of illness related to hepatic insufficiency within 30 days prior to screening, and no significant change in disease status from screening to check-in (Day -1); * On a stable medication regimen, defined as not starting any new prescription or non-prescription medications or significant changes in dose of such medications within 30 days prior to dosing of investigational drug on Day 1; * Abnormal laboratory values must be clinically acceptable, as judged by the Investigator; * Negative result of the human immunodeficiency virus (HIV) screen and the hepatitis B screen. Note hepatically impaired participants with chronic hepatitis C infection (duration \> 6 months) are eligible for enrollment, if stable. Inclusion criteria Specific for Healthy Participants: * Participants must meet demographically-matched criteria to one of the participants enrolled in this study with moderate hepatic impairment based on sex, age (±10 years), and BMI (±20%); * Medically normal with no clinically significant illness or disease and no significant abnormal findings at the baseline physical examination; * Participant has normal (or abnormal and clinically insignificant) laboratory values at screening. A single test repeat at the discretion of the Investigator is allowed during the screening period to determine eligibility; * Negative result from the HIV screen, the hepatitis B screen, and the hepatitis C screen.
Exclusion criteria
* Pregnant or breastfeeding; * At least 7 days prior to check-in, and throughout the blood sample collection period, consumption of any food or any beverage containing grapefruit or grapefruit juice, Seville oranges, apple or orange juice, vegetables from the mustard green family (e.g., kale, broccoli, watercress, collard greens, kohlrabi, cauliflower, Brussels sprouts, mustard greens) and charbroiled meats; * Strenuous exercise within 4 days prior to check-in; * Recent history of myopathy or muscle injury; * Consumption of alcohol within 48 hours prior to check-in on Day -1 (as confirmed by alcohol test); * A history or presence of any form of cancer within the 5 years prior to check-in, with the exception of excised basal cell or squamous cell carcinoma of the skin, or cervical carcinoma in situ or breast carcinoma in situ that has been excised or resected completely and is without evidence of local recurrence or metastasis; * History or presence of unexplained syncope or family history of sudden death, or any medical condition or disease which, in the opinion of the Investigator, may place the participant at unacceptable risk for study participation; * Donated or lost more than 350 mL of blood or blood products within 56 days prior to screening, or donated plasma within 7 days of dosing; * Participant has any evidence of renal impairment; serum creatinine greater than 1.5 times the upper limit of normal at screening or check-in; * Participant's urine tested positive at screening and/or check-in for any of the following (unless the positive drug screen in hepatic participants is due to prescription drug use and is approved by the investigator and the Sponsor's Medical Monitor): opioids, amphetamines and methamphetamines, cannabinoids, benzodiazepines, barbiturates, cocaine, cotinine (healthy participants only), methylenedioxymethamphetamine (MDMA or ecstasy), methadone, phencyclidine, tri-cyclic antidepressants, or alcohol; * Currently taking a strong inducer of the cytochrome P450 3A4 (CYP3A4) enzyme, (e.g. carbamazepine, phenobarbital, phenytoin, rifampin, or St. John's wort) or use of a strong CYP3A4 inducer within 14 days prior to check-in and through discharge, unless deemed acceptable by the Investigator, Medical Monitor, and/or the Sponsor; * Currently taking a strong inhibitor of the CYP3A4 enzyme, (e.g. boceprevir, clarithromycin, conivaptan, grapefruit juice, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, or voriconazoleor) or use of a strong CYP3A4 inhibitor within 14 days prior to check-in and through discharge, unless deemed acceptable by the Investigator, Medical Monitor, and/or the Sponsor; * Participated in any clinical study of an investigational product within 30 days prior to dosing or within 5 half-lives after dosing; * History within one year prior to check-in of illicit drug abuse; * Significant infection or hospitalization within 28 days prior to check-in on Day -1.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AUC0-inf of CCX168-M1 | Up to Day 18 |
| Apparent Oral Clearance (CL/F) of Avacopan | Up to Day 18 |
| CL/F of CCX168-M1 | Up to Day 18 |
| Apparent Volume of Distribution (Vz/F) of Avacopan | Up to Day 18 |
| Vz/F of CCX168-M1 | Up to Day 18 |
| Maximum Plasma Concentration (Cmax) of Avacopan | Up to Day 18 |
| Cmax of CCX168-M1 | Up to Day 18 |
| Time of Cmax (Tmax) of Avacopan | Up to Day 18 |
| Tmax of CCX168-M1 | Up to Day 18 |
| Terminal Phase Rate Constant of Avacopan | Up to Day 18 |
| Terminal Phase Rate Constant of CCX168-M1 | Up to Day 18 |
| Apparent Terminal Half-life (t1/2z) of Avacopan | Up to Day 18 |
| t1/2z of CCX168-M1 | Up to Day 18 |
| Area Under the Plasma Concentration-time Curve (AUC) from Time 0 to Time t (time of last quantifiable plasma concentration) (AUClast) of Avacopan | Up to Day 18 |
| AUClast of CCX168-M1 | Up to Day 18 |
| AUC from Time 0 to Time 6 Hours Post-dose (AUC0-6h) of Avacopan | Up to Hour 6 |
| AUC0-6h of CCX168-M1 | Up to Hour 6 |
| AUC from Time 0 to Time 12 Hours Post-dose (AUC0-12h) of Avacopan | Up to Hour 12 |
| AUC0-12h of CCX168-M1 | Up to Hour 12 |
| AUC from Time 0 to Infinity (AUC0-inf) of Avacopan | Up to Day 18 |
Secondary
| Measure | Time frame |
|---|---|
| Number of Participants Experiencing Adverse Events | Up to Day 18 |
Countries
United States
Outcome results
None listed